GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk

GeoVax Labs, Inc.

Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.
Cash balance fell to $768,859 from $6.45M at Dec 31, 2023, a decline of ~$5.7M.
R&D expenses rose to $4.43M from $2.82M, driven by manufacturing costs for clinical trials.
Phase 2 GEO-CM04S1 COVID vaccine booster trial showed statistically significant neutralizing antibody increases against multiple variants.
Gedeptin Phase 1/2 for head and neck cancer completed enrollment; expected to complete Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeoVax Labs, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended March 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-017040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.